Literature DB >> 25637051

T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis.

Norbert-Claude Gorin1, Myriam Labopin2, Simona Piemontese3, William Arcese4, Stella Santarone5, He Huang6, Giovanna Meloni7, Felicetto Ferrara8, Dietrich Beelen9, Miguel Sanz10, Andrea Bacigalupo11, Fabio Ciceri12, Audrey Mailhol13, Arnon Nagler14, Mohamad Mohty2.   

Abstract

Adult patients with acute leukemia in need of a transplant but without a genoidentical donor are usually considered upfront for transplantation with stem cells from any other allogeneic source, rather than autologous stem cell transplantation. We used data from the European Society for Blood and Marrow Transplantation and performed a matched pair analysis on 188 T-cell-replete haploidentical and 356 autologous transplants done from January 2007 to December 2012, using age, diagnosis, disease status, cytogenetics, and interval from diagnosis to transplant as matching factors. "Haploidentical expert" centers were defined as having reported more than five haploidentical transplants for acute leukemia (median value for the study period). The median follow-up was 28 months. Multivariate analyses, including type of transplant categorized into three classes ("haploidentical regular", "haploidentical expert" and autologous), conditioning intensity (reduced intensity versus myeloablative conditioning) and the random effect taking into account associations related to matching, showed that non-relapse mortality was higher following haploidentical transplants in expert (HR: 4.7; P=0.00004) and regular (HR: 8.98; P<10(-5)) centers. Relapse incidence for haploidentical transplants was lower in expert centers (HR:0.39; P=0.0003) but in regular centers was similar to that for autologous transplants. Leukemia-free survival and overall survival rates were higher following autologous transplantation than haploidentical transplants in regular centers (HR: 1.63; P=0.008 and HR: 2.31; P=0.0002 respectively) but similar to those following haploidentical transplants in expert centers. We conclude that autologous stem cell transplantation should presently be considered as a possible alternative to haploidentical transplantation in regular centers that have not developed a specific expert program. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Year:  2015        PMID: 25637051      PMCID: PMC4380730          DOI: 10.3324/haematol.2014.111450

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  34 in total

1.  History of hematopoietic stem cell transplantation: evolution and perspectives.

Authors:  Alois Gratwohl; Dietger Niederwieser
Journal:  Curr Probl Dermatol       Date:  2012-02-17

2.  Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.

Authors:  Can-Lan Sun; Liton Francisco; Toana Kawashima; Wendy Leisenring; Leslie L Robison; K Scott Baker; Daniel J Weisdorf; Stephen J Forman; Smita Bhatia
Journal:  Blood       Date:  2010-07-23       Impact factor: 22.113

3.  Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission.

Authors:  Norbert-Claude Gorin; Myriam Labopin; Josy Reiffers; Noel Milpied; Didier Blaise; Francis Witz; Theo de Witte; Giovanna Meloni; Michel Attal; Teresa Bernal; Vanderson Rocha
Journal:  Blood       Date:  2010-05-17       Impact factor: 22.113

4.  The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission.

Authors:  Xiao-Jun Huang; Hong-Hu Zhu; Ying-Jun Chang; Lan-Ping Xu; Dai-Hong Liu; Xiao-Hui Zhang; Bin Jiang; Qian Jiang; Hao Jiang; Yu-Hong Chen; Huan Chen; Wei Han; Kai-Yan Liu; Yu Wang
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

5.  Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.

Authors:  Thomas Büchner; Richard F Schlenk; Markus Schaich; Konstanze Döhner; Rainer Krahl; Jürgen Krauter; Gerhard Heil; Utz Krug; Maria Cristina Sauerland; Achim Heinecke; Daniela Späth; Michael Kramer; Sebastian Scholl; Wolfgang E Berdel; Wolfgang Hiddemann; Dieter Hoelzer; Rüdiger Hehlmann; Joerg Hasford; Verena S Hoffmann; Hartmut Döhner; Gerhard Ehninger; Arnold Ganser; Dietger W Niederwieser; Markus Pfirrmann
Journal:  J Clin Oncol       Date:  2012-09-10       Impact factor: 44.544

6.  Haplo-BMT: which approach?

Authors:  Andrea Velardi
Journal:  Blood       Date:  2013-01-31       Impact factor: 22.113

Review 7.  Haploidentical hematopoietic stem cell transplantation with a megadose T-cell-depleted graft: harnessing natural and adaptive immunity.

Authors:  Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

8.  Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research.

Authors:  Armand Keating; Gisela DaSilva; Waleska S Pérez; Vikas Gupta; Corey S Cutler; Karen K Ballen; Mitchell S Cairo; Bruce M Camitta; Richard E Champlin; James L Gajewski; Hillard M Lazarus; Michael Lill; David I Marks; Chadi Nabhan; Gary J Schiller; Gerald Socie; Jeffrey Szer; Martin S Tallman; Daniel J Weisdorf
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

9.  Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.

Authors:  Anna Maria Raiola; Alida Dominietto; Anna Ghiso; Carmen Di Grazia; Teresa Lamparelli; Francesca Gualandi; Stefania Bregante; Maria Teresa Van Lint; Simona Geroldi; Silvia Luchetti; Filippo Ballerini; Maurizio Miglino; Riccardo Varaldo; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-29       Impact factor: 5.742

10.  HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease.

Authors:  Javier Bolaños-Meade; Ephraim J Fuchs; Leo Luznik; Sophie M Lanzkron; Christopher J Gamper; Richard J Jones; Robert A Brodsky
Journal:  Blood       Date:  2012-09-06       Impact factor: 22.113

View more
  12 in total

1.  Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of a Matched Identical Sibling: A Meta-Analysis.

Authors:  Zhichao Li; Yinmei Liu; Qing Wang; Linjun Chen; Liyuan Ma; Siguo Hao
Journal:  Acta Haematol       Date:  2019-02-26       Impact factor: 2.195

2.  Hematopoietic cell transplantation for acute leukemia: selecting donors.

Authors:  Mary Eapen
Journal:  Haematologica       Date:  2015-04       Impact factor: 9.941

3.  Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission.

Authors:  F Saraceni; B Bruno; R M Lemoli; G Meloni; W Arcese; M Falda; F Ciceri; E P Alessandrino; G Specchia; R Scimè; R Raimondi; A Bacigalupo; A Bosi; F Onida; A Rambaldi; F Bonifazi; A Olivieri
Journal:  Bone Marrow Transplant       Date:  2016-09-26       Impact factor: 5.483

Review 4.  Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects.

Authors:  N-C Gorin; S Giebel; M Labopin; B N Savani; M Mohty; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-08-17       Impact factor: 5.483

5.  Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.

Authors:  Matthew P Mulé; Gabriel N Mannis; Brent L Wood; Jerald P Radich; Jimmy Hwang; Nestor R Ramos; Charalambos Andreadis; Lloyd Damon; Aaron C Logan; Thomas G Martin; Christopher S Hourigan
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-17       Impact factor: 5.742

6.  Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR.

Authors:  M Mizutani; M Hara; H Fujita; J Aoki; H Kanamori; K Ohashi; K Usuki; T Fukuda; T Chou; J Tanaka; Y Atsuta; A Takami
Journal:  Bone Marrow Transplant       Date:  2016-01-25       Impact factor: 5.483

7.  Haploidentical stem cell transplantation (HaploSCT) for patients with acute leukemia-an update on behalf of the ALWP of the EBMT.

Authors:  Arnon Nagler; Annalisa Ruggeri
Journal:  Bone Marrow Transplant       Date:  2019-08       Impact factor: 5.483

8.  Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes.

Authors:  Sijian Yu; Zhiping Fan; Liping Ma; Yu Wang; Fen Huang; Qing Zhang; Jiafu Huang; Shunqing Wang; Na Xu; Li Xuan; Mujun Xiong; Lijie Han; Zhiqiang Sun; Hongyu Zhang; Hui Liu; Guopan Yu; Pengcheng Shi; Jun Xu; Meiqing Wu; Ziwen Guo; Yiying Xiong; Chongyang Duan; Jing Sun; Qifa Liu; Yu Zhang
Journal:  JAMA Netw Open       Date:  2021-07-01

Review 9.  How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?

Authors:  Ying-Jun Chang; Leo Luznik; Ephraim J Fuchs; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2016-04-12       Impact factor: 17.388

Review 10.  Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Catherine J Lee; Bipin N Savani; Mohamad Mohty; Myriam Labopin; Annalisa Ruggeri; Christoph Schmid; Frédéric Baron; Jordi Esteve; Norbert C Gorin; Sebastian Giebel; Fabio Ciceri; Arnon Nagler
Journal:  Haematologica       Date:  2017-09-07       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.